Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.
Federica Morano(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan), Rossana Berardi(Marche Polytechnic University), Monica Niger(Fondazione IRCCS Istituto Nazionale dei Tumori), Mario Scartozzi(University of Cagliari), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Sara Lonardi(Istituto Oncologico Veneto), Elisa Giommoni(Azienda Ospedaliero-Universitaria Careggi), Lorenza Rimassa(Humanitas University), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Samantha Di Donato(Ospedale di Prato Santo Stefano), Giovanni Gerardo Cardellino(Ospedale Santa Maria della Misericordia di Udine), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Giuliani(Ospedale San Paolo), Giovanni Luca Frassineti, Gianluca Tomasello(Istituti Ospitalieri di Cremona), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Graziella Pinotti(Medica (Italy)), Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 0
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k